These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 18972590

  • 1. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
    Lee TJ, Kim KH, Chun JK, Kim DS.
    Yonsei Med J; 2008 Oct 31; 49(5):714-8. PubMed ID: 18972590
    [Abstract] [Full Text] [Related]

  • 2. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr 31; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 3. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 31; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 4. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
    Sundel RP, Baker AL, Fulton DR, Newburger JW.
    J Pediatr; 2003 Jun 31; 142(6):611-6. PubMed ID: 12838187
    [Abstract] [Full Text] [Related]

  • 5. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb 31; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 6. Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for Intravenous Immunoglobulin-Resistant Kawasaki Disease.
    Jang H, Kim KY, Kim DS.
    Yonsei Med J; 2018 Jan 31; 59(1):113-118. PubMed ID: 29214785
    [Abstract] [Full Text] [Related]

  • 7. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov 31; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

  • 8. Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate.
    Ahn SY, Kim DS.
    Scand J Rheumatol; 2005 Nov 31; 34(2):136-9. PubMed ID: 16095010
    [Abstract] [Full Text] [Related]

  • 9. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
    Manlhiot C, Yeung RS, Chahal N, McCrindle BW.
    Pediatr Allergy Immunol; 2010 May 31; 21(3):515-21. PubMed ID: 20546528
    [Abstract] [Full Text] [Related]

  • 10. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
    Kuo HC, Wang CL, Liang CD, Yu HR, Chen HH, Wang L, Yang KD.
    J Microbiol Immunol Infect; 2007 Oct 31; 40(5):395-400. PubMed ID: 17932598
    [Abstract] [Full Text] [Related]

  • 11. A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate.
    Lee MS, An SY, Jang GC, Kim DS.
    Yonsei Med J; 2002 Aug 31; 43(4):527-32. PubMed ID: 12205742
    [Abstract] [Full Text] [Related]

  • 12. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
    DU ZD, Zhao D, DU JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF, Beijing Kawasaki Disease Epidemilogy Study Grou.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 27; 87(44):3119-21. PubMed ID: 18269869
    [Abstract] [Full Text] [Related]

  • 13. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S.
    J Pediatr; 2000 Aug 27; 137(2):177-80. PubMed ID: 10931408
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
    Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y.
    Arthritis Rheum; 2013 Mar 27; 65(3):805-14. PubMed ID: 23440694
    [Abstract] [Full Text] [Related]

  • 15. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
    Pediatr Infect Dis J; 2008 Feb 27; 27(2):155-60. PubMed ID: 18174868
    [Abstract] [Full Text] [Related]

  • 16. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease.
    Sittiwangkul R, Pongprot Y, Silvilairat S, Phornphutkul C.
    Singapore Med J; 2006 Sep 27; 47(9):780-4. PubMed ID: 16924360
    [Abstract] [Full Text] [Related]

  • 17. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.
    Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, Matsuishi T.
    J Pediatr; 2006 Aug 27; 149(2):237-40. PubMed ID: 16887442
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S.
    J Rheumatol; 2012 Apr 27; 39(4):864-7. PubMed ID: 22337241
    [Abstract] [Full Text] [Related]

  • 19. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin.
    Tsai MH, Huang YC, Yen MH, Li CC, Chiu CH, Lin PY, Lin TY, Chang LY.
    J Pediatr; 2006 Jan 27; 148(1):38-43. PubMed ID: 16423595
    [Abstract] [Full Text] [Related]

  • 20. [Methylprednisolone pulse therapy in Kawasaki disease].
    Miura M, Matsuoka M, Kohno K, Ohki H, Yoshiba S.
    Nihon Rinsho; 2008 Feb 27; 66(2):338-42. PubMed ID: 18265457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.